Narrative Update: Tatva Chintan Pharma Chem Analyst Price Target Revision
Analysts have raised their fair value estimate for Tatva Chintan Pharma Chem from ₹865 to ₹1,035. This revision is based on improved profit margin expectations, which offset slightly reduced revenue growth projections and a marginally lower future P/E ratio.
What's in the News
- The Board of Directors of Tatva Chintan Pharma Chem will hold a meeting on October 31, 2025, at 11:30 AM IST to review and approve the standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2025. (Company Filing)
- The company will consider, and based on committee recommendations, has approved the appointment of Mr. Ajesh Kumar Mohanan Pillai as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective October 31, 2025. (Company Filing)
Valuation Changes
- Fair Value: Increased from ₹865 to ₹1,035, reflecting a rise in the estimated intrinsic value per share.
- Discount Rate: Decreased slightly from 13.48% to 13.40%, indicating a marginally lower required rate of return.
- Revenue Growth: Moderated from 23.55% to 22.89%, suggesting a slightly reduced growth outlook.
- Net Profit Margin: Improved from 13.52% to 14.96%, demonstrating expectations for higher profitability.
- Future P/E: Lowered from 31.45x to 30.01x, which points to a modest reduction in the projected valuation multiple.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.